UBS Group AG Cuts Position in Celldex Therapeutics, Inc. $CLDX

UBS Group AG lessened its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 21.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 326,462 shares of the biopharmaceutical company’s stock after selling 89,985 shares during the period. UBS Group AG owned about 0.49% of Celldex Therapeutics worth $8,867,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Wellington Management Group LLP increased its stake in shares of Celldex Therapeutics by 10.8% in the 3rd quarter. Wellington Management Group LLP now owns 5,800,003 shares of the biopharmaceutical company’s stock valued at $150,046,000 after purchasing an additional 567,677 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Celldex Therapeutics by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 4,027,407 shares of the biopharmaceutical company’s stock valued at $109,384,000 after purchasing an additional 72,817 shares in the last quarter. Bellevue Group AG increased its stake in shares of Celldex Therapeutics by 7.6% in the 3rd quarter. Bellevue Group AG now owns 3,557,669 shares of the biopharmaceutical company’s stock valued at $92,037,000 after purchasing an additional 250,100 shares in the last quarter. Commodore Capital LP increased its stake in shares of Celldex Therapeutics by 7.8% in the 2nd quarter. Commodore Capital LP now owns 3,450,000 shares of the biopharmaceutical company’s stock valued at $70,208,000 after purchasing an additional 250,000 shares in the last quarter. Finally, Eventide Asset Management LLC increased its stake in shares of Celldex Therapeutics by 37.1% in the 3rd quarter. Eventide Asset Management LLC now owns 1,859,095 shares of the biopharmaceutical company’s stock valued at $48,096,000 after purchasing an additional 502,909 shares in the last quarter.

Celldex Therapeutics Stock Performance

CLDX stock opened at $31.34 on Monday. Celldex Therapeutics, Inc. has a 12-month low of $18.55 and a 12-month high of $35.79. The stock has a market cap of $2.46 billion, a price-to-earnings ratio of -7.36 and a beta of 0.98. The business’s 50-day moving average is $31.98 and its 200 day moving average is $28.10.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.15) by ($0.03). The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.80 million. As a group, equities analysts forecast that Celldex Therapeutics, Inc. will post -4.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on CLDX. Wolfe Research upgraded Celldex Therapeutics from a “peer perform” rating to an “outperform” rating and set a $44.00 price target for the company in a research note on Monday, March 23rd. Wells Fargo & Company lifted their price target on Celldex Therapeutics from $38.00 to $54.00 and gave the company an “overweight” rating in a research note on Wednesday, May 13th. Stifel Nicolaus restated a “buy” rating and issued a $68.00 price target (up from $58.00) on shares of Celldex Therapeutics in a research note on Thursday, February 26th. The Goldman Sachs Group lifted their price target on Celldex Therapeutics from $30.00 to $34.00 and gave the company a “neutral” rating in a research note on Monday, March 2nd. Finally, Wall Street Zen upgraded Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $49.78.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.